News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premium here.

• 127% year-over-year increase in ColoAlert revenue
• Mid-year cash balance of $26 Million

BERKELEY, Calif. and MAINZ, Germany, Sept. 07, 2022 (GLOBE NEWSWIRE) — Mainz Biomed N.V. (NASDAQ: MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today financial results for the first half of the fiscal year ended June 30, 2022.

Key Corporate & Product Development Highlights

• Accelerated international commercial activities for ColoAlert, the Company’s highly efficacious and easy-to-use detection test for colorectal cancer (CRC)
• Appointed Darin Leigh, former Abbott and Luminex executive, as Chief Commercial Officer
• Established partnership with Dante Labs to market ColoAlert in Italy and the United Arab Emirates
• Initiated and enrolled the first patient in an international clinical study (ColoFuture) evaluating the integration of novel mRNA biomarkers into ColoAlert – potentially upgrading its technical profile to achieve “gold standard” status for CRC at-home testing
• Received supportive feedback from the U.S. Food and Drug Administration (FDA) on ColoAlert’s pre-submission package for its U.S. pivotal clinical trial set to commence in Q4 2022
• Achieved multiple preclinical milestones supporting the continued development of PancAlert, a potential first-in-class…